|
| | | | |
|
 | | LP299V PROBIOTIC PENETRATES THE INDIAN MARKET | | | Institut Rosell-Lallemand | | 17/12/2007 | | | Aristo Pharmaceuticals and Ranbaxy: two partners of choice for Institut Rosell-Lallemand
Montreal (Canada) — December 17th, 2007 – Institut Rosell-Lallemand announced today that dietary supplements based on clinically documented probiotic Lactobacillus plantarum 299v have been launched in India. Two distribution agreements were signed earlier this year with major players in the Indian pharmaceutical market — Ranbaxy and Aristo Pharmaceuticals — which guarantee Institut Rosell-Lallemand complementary distribution channels to gain access to the entire market in that country. India is the fourth largest pharmaceutical market in the world, offering huge growth potential for the dietary supplement segment.
An initial agreement was signed last May with Aristo Pharmaceuticals, a dynamic and rapidly growing pharmaceutical company with an established promotion network in the general practitioner and pharmaceutical communities. Aristo Pharmaceuticals will market the probiotic under the Darolac IBS trademark. The second partnership was concluded in September with Ranbaxy, one of the top ten generic drug companies in the world. Ranbaxy will launch the probiotic among gastroenterologists and other gastro specialists under the trade name of Leviosa299v. These agreements open two complementary distribution channels for a clinically documented probiotic that targets a growing health issue in India — Irritable Bowel Syndrome (IBS). IBS prevalence in that country has now reached the same level as in Europe, Japan and North America, estimated at around 10-20% of the population.
"We are highly confident that the solid presence and reputation of our partners and the synergy of their distribution strategies will achieve optimal penetration of the Indian market,” underlined Valérie Delahaye-Sarraute, Deputy General Manager of Institut Rosell-Lallemand. “Recent regulatory progress, such as the adoption of the Food Safety and Standard Bill that officially recognizes the status of dietary supplements in India, together with a cultural tradition of complementary and alternative medicine, offers huge potential for scientifically supported probiotics in India.”
Irritable Bowel Syndrome is the most common functional disorder of the gastrointestinal tract, characterized by abdominal pain, bloating and irregular bowel function. Lp299v’s unique action and set of benefits for IBS patients are well documented and protected by different patents. A placebo-controlled randomized study has shown that intestinal discomfort was improved by up to 95% in patients (compared to 15% with placebo), while abdominal pain and bloating were also significantly decreased . Lp299v was originally selected by Swedish biotech company Probi AB, and an exclusive licensing agreement covering the dietary supplement market was signed with Institut Rosell-Lallemand at the end of 2003. | |
|
| | | View similar articles: | | |
| | | |
|
 | People who viewed this article were also interested in |  | |  |
|